The Department for Health and Social Care has asked NICE to conduct an appraisal of Bulevirtide for treating chronic hepatitis D.
Please note that following on from a request received from the company, the timelines for this appraisal have been revised and the appraisal is now anticipated to begin in mid-March 2021 when we will write to you about how you can get involved. The deadline for submissions is expected in approximately mid May 2021.
These timelines are based on a request from the company to reschedule the initial date set by NICE, in order to facilitate a suitably comprehensive submission.